Cover Image
市場調查報告書

披衣菌感染:全球臨床實驗檢討

Chlamydia Infections Global Clinical Trials Review, H1, 2017

出版商 GlobalData 商品編碼 177202
出版日期 內容資訊 英文 58 Pages
訂單完成後即時交付
價格
Back to Top
披衣菌感染:全球臨床實驗檢討 Chlamydia Infections Global Clinical Trials Review, H1, 2017
出版日期: 2017年05月31日 內容資訊: 英文 58 Pages
簡介

披衣菌感染是由非常細小的Chlamydia trachomatis(砂眼披衣菌)引起的性感染病(STI)。會影響頸椎、尿道、輸卵管、子宮、鼻咽、副睪丸等部位。

本報告提供披衣菌感染的治療藥相關之臨床實驗調查分析,提供您臨床實驗數及受驗人數,各階段及Phase狀況,有潛力企業,正在開發的治療藥的資訊,臨床實驗簡介等相關的系統性資訊。

目錄

簡介

各地區的臨床實驗

  • 各國臨床實驗趨勢
    • 亞太地區的主要國家
    • 歐洲的主要國家
    • 北美的主要國家
    • 中東·非洲的主要國家
    • 中南美的主要國家

G7各國的臨床實驗:感染性疾病臨床實驗上披衣菌感染所佔的比例

G7各國的臨床實驗:Phase別

G7各國的臨床實驗:各階段

E7各國的臨床實驗:感染性疾病臨床實驗上披衣菌感染所佔的比例

E7各國的臨床實驗:Phase別

E7各國的臨床實驗:各階段

各方面的臨床實驗

各階段臨床實驗

評估項目別臨床實驗

未完成的臨床實驗

一定期間所採用的實驗對象

贊助商類別臨床實驗

有潛力的贊助商

  • 披衣菌感染的治療藥臨床實驗的主要參與企業

有潛力藥物

臨床實驗簡介

  • 主要企業臨床實驗概要
    • kyorin製藥集團
    • Endo International plc
    • Cempra Pharmaceuticals, Inc.
    • ActivBiotics Pharma, LLC
    • Actavis plc
  • 主要大學·研究機關·醫院臨床實驗概要
    • University of California, San Francisco
    • Johns Hopkins University
    • Centers for Disease Control and Prevention
    • National Heart, Lung, and Blood Institute
    • University of Pittsburgh
    • The University of Melbourne
    • Washington University School of Medicine
    • London School of Hygiene & Tropical Medicine
    • Population Council
    • Barts and The London NHS Trust

主要的臨床簡介

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GDHC4273CTIDB

GlobalData's clinical trial report, "Chlamydia Infections Global Clinical Trials Review, H1, 2017" provides an overview of Chlamydia Infections clinical trials scenario. This report provides top line data relating to the clinical trials on Chlamydia Infections. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table of Contents

Table of Contents

Table of Contents 2

  • List of Tables 3
  • List of Figures 3
  • Report Guidance 4
  • GlobalData Clinical Trials Report Coverage 5
  • Clinical Trials by Region 6
  • Clinical Trials and Average Enrollment by Country 7
  • Top Five Countries Contributing to Clinical Trials in Asia-Pacific 9
  • Top Five Countries Contributing to Clinical Trials in Europe 10
  • Top Countries Contributing to Clinical Trials in North America 11
  • Top Five Countries Contributing to Clinical Trials in Middle East and Africa 12
  • Clinical Trials by G7 Countries: Proportion of Chlamydia Infections to Infectious Disease Clinical Trials 13
  • Clinical Trials by Phase in G7 Countries 14
  • Clinical Trials in G7 Countries by Trial Status 15
  • Clinical Trials by E7 Countries: Proportion of Chlamydia Infections to Infectious Disease Clinical Trials 16
  • Clinical Trials by Phase 17
  • In Progress Trials by Phase 18
  • Clinical Trials by Trial Status 19
  • Clinical Trials by End Point Status 20
  • Subjects Recruited Over a Period of Time 21
  • Clinical Trials by Sponsor Type 22
  • Prominent Sponsors 23
  • Top Companies Participating in Chlamydia Infections Therapeutics Clinical Trials 24
  • Prominent Drugs 25
  • Clinical Trial Profile Snapshots 26

Appendix 56

  • Abbreviations 56
  • Definitions 56
  • Research Methodology 57
  • Secondary Research 57
  • About GlobalData 58
  • Contact Us 58
  • Source 58

List of Tables

List of Tables

  • Chlamydia Infections Therapeutics, Global, Clinical Trials by Region, 2017* 6
  • Chlamydia Infections Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 7
  • Chlamydia Infections Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 8
  • Chlamydia Infections Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2017* 9
  • Chlamydia Infections Therapeutics Clinical Trials, Europe, Top Five Countries, 2017* 10
  • Chlamydia Infections Therapeutics Clinical Trials, North America, Top Countries, 2017* 11
  • Chlamydia Infections Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2017* 12
  • Proportion of Chlamydia Infections to Infectious Disease Clinical Trials, G7 Countries (%), 2017* 13
  • Chlamydia Infections Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 14
  • Chlamydia Infections Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 15
  • Proportion of Chlamydia Infections to Infectious Disease Clinical Trials, E7 Countries (%), 2017* 16
  • Chlamydia Infections Therapeutics, Global, Clinical Trials by Phase, 2017* 17
  • Chlamydia Infections Therapeutics, Global, Clinical Trials In Progress by Phase 2017* 18
  • Chlamydia Infections Therapeutics, Global, Clinical Trials by Trial Status, 2017* 19
  • Chlamydia Infections Therapeutics Clinical Trials, Global, by End Point Status, 2017* 20
  • Chlamydia Infections Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 21
  • Chlamydia Infections Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2017* 22
  • Chlamydia Infections Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 23
  • Chlamydia Infections Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 24
  • Chlamydia Infections Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 25

List of Figures

List of Figures

  • Chlamydia Infections Therapeutics, Global, Clinical Trials by Region (%), 2017* 6
  • Chlamydia Infections Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 7
  • Chlamydia Infections Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 8
  • Chlamydia Infections Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2017* 9
  • Chlamydia Infections Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2017* 10
  • Chlamydia Infections Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2017* 12
  • Proportion of Chlamydia Infections to Infectious Disease Clinical Trials, G7 Countries (%), 2017* 13
  • Chlamydia Infections Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 14
  • Chlamydia Infections Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 15
  • Proportion of Chlamydia Infections to Infectious Disease Clinical Trials, E7 Countries (%), 2017* 16
  • Chlamydia Infections Therapeutics, Global, Clinical Trials by Phase (%), 2017* 17
  • Chlamydia Infections Therapeutics, Global, Clinical Trials In Progress by Phase, 2017* 18
  • Chlamydia Infections Therapeutics, Global, Clinical Trials by Trial Status, 2017* 19
  • Chlamydia Infections Therapeutics Clinical Trials, Global, by End Point Status, 2017* 20
  • Chlamydia Infections Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 21
  • Chlamydia Infections Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2017* 22
  • Chlamydia Infections Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 23
  • Chlamydia Infections Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 24
  • Chlamydia Infections Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 25
  • GlobalData Methodology 57
Back to Top